Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Loss of Wasl improves pancreatic cancer outcome
Ana Hidalgo-Sastre, Judit Desztics, Zahra Dantes, Katharina Schulte, Hilal Kabadayi Ensarioglu, Blessing Bassey-Archibong, Rupert Öllinger, Thomas Engleiter, Lyndsay Rayner, Henrik Einwächter, Juliet M. Daniel, Ali Sameer Abdulghani Altaee, Katia Steiger, Marina Lesina, Roland Rad, Maximilian Reichert, Guido von Figura, Jens T. Siveke, Roland M. Schmid, Clara Lubeseder-Martellato
Ana Hidalgo-Sastre, Judit Desztics, Zahra Dantes, Katharina Schulte, Hilal Kabadayi Ensarioglu, Blessing Bassey-Archibong, Rupert Öllinger, Thomas Engleiter, Lyndsay Rayner, Henrik Einwächter, Juliet M. Daniel, Ali Sameer Abdulghani Altaee, Katia Steiger, Marina Lesina, Roland Rad, Maximilian Reichert, Guido von Figura, Jens T. Siveke, Roland M. Schmid, Clara Lubeseder-Martellato
View: Text | PDF
Research Article Oncology

Loss of Wasl improves pancreatic cancer outcome

  • Text
  • PDF
Abstract

Several studies have suggested an oncogenic role for the neural Wiskott-Aldrich syndrome protein (N-WASP, encoded by the Wasl gene), but thus far, little is known about its function in pancreatic ductal adenocarcinoma (PDAC). In this study, we performed in silico analysis of WASL expression in PDAC patients and found a correlation between low WASL expression and prolonged survival. To clarify the role of Wasl in pancreatic carcinogenesis, we used 2 oncogenic Kras–based PDAC mouse models with pancreas-specific Wasl deletion. In line with human data, both mouse models had an increased survival benefit due to either impaired tumor development in the presence of the tumor suppressor Trp53 or the delayed tumor progression and senescent phenotype upon genetic ablation of Trp53. Mechanistically, loss of Wasl resulted in cell-autonomous senescence through displacement of the N-WASP binding partners WASP-interacting protein (WIP) and p120ctn; vesicular accumulation of GSK3β, as well as YAP1 and phosphorylated β-catenin, which are components of the destruction complex; and upregulation of Cdkn1a(p21), a master regulator of senescence. Our findings, thus, indicate that Wasl functions in an oncogenic manner in PDAC by promoting the deregulation of the p120-catenin/β-catenin/p21 pathway. Therefore, strategies to reduce N-WASP activity might improve the survival outcomes of PDAC patients.

Authors

Ana Hidalgo-Sastre, Judit Desztics, Zahra Dantes, Katharina Schulte, Hilal Kabadayi Ensarioglu, Blessing Bassey-Archibong, Rupert Öllinger, Thomas Engleiter, Lyndsay Rayner, Henrik Einwächter, Juliet M. Daniel, Ali Sameer Abdulghani Altaee, Katia Steiger, Marina Lesina, Roland Rad, Maximilian Reichert, Guido von Figura, Jens T. Siveke, Roland M. Schmid, Clara Lubeseder-Martellato

×

Figure 2

CKP-NΔPanc mice have improved survival and develop tumors that express senescent markers.

Options: View larger image (or click on image) Download as PowerPoint
CKP-NΔPanc mice have improved survival and develop tumors that express s...
(A) Immunohistochemical staining showing the lack of N-WASP expression in pancreata of CKP-NΔPanc mice. Scale bars: 50 μM. The inserts show the islets of Langerhans (I.L.) as an internal positive control for N-WASP staining. (B) Kaplan-Meier survival curves for mice of the indicated genotypes. CKP-Nhet (n = 12) and CKP-NΔPanc (n = 10). Log-rank test. (C) Murine tumor specimen were stained for the proliferation marker Ki67. The number of Ki67-positive tumor cells was quantified per relative area. Data represent mean ± SEM; Student′s t test. (D) Representative pictures of tumors developed by the indicated mice. Scale bars: 50 μM. (E) SA–β-galactosidase staining of cryosections of murine tumors. Scale bars: 50 μM. Inserts show magnification of the black boxes. (F) The amount of SA–β-galactosidase–positive cells was quantified in the tumor cell and stromal cell compartment. Data represent the mean of 2 mice per group ± SEM. Student′s t test. (G) The expression of the indicated genes was analyzed by RT-PCR. Data represent the mean of 4 of 5 tumors per group ± SEM. Student′s t test. (H) Enrichment plots generated by the GSEA tool. The IL-6/JAK/STAT3 and TNFA signaling via NF-κB signaling pathways, as well as the IFNG response signatures, were enriched in the CKP-NΔPanc tumors.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts